Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis meds may quietly shield arteries, small study hints

NCT ID NCT07169682

Knowledge-focused Sponsor: National and Kapodistrian University of Athens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study checked if newer psoriasis drugs (IL17/23 inhibitors) also improve artery stiffness, a sign of heart disease. Researchers followed 66 people with moderate-to-severe psoriasis for a year, measuring pulse wave velocity (PWV) and other markers. The goal was to see if these drugs might have hidden heart benefits beyond clearing skin.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IL17 or IL23 inhibitor (drug)
What this could lead to
If the drugs improve artery stiffness, it could suggest they also lower heart disease risk in people with psoriasis.
What could go wrong
This is a small, observational study, not a large trial. It only measured a marker (artery stiffness), not actual heart attacks or strokes, so the real benefit is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

66 people

The number who actually took part.

Started

Sep 2021

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive patients with plaque psoriasis with or without psoriatic arthritis, who were monitored in the outpatient department for psoriasis of "Andreas Syngros" hospital for skin diseases and were planed to start treatment with an IL17 inhibitor or an IL23 inhibitor on a conventional systemic agent/apremilast

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Moderate-to-severe psoriasis (Psoriasis Area Severity Index (PASI) score \> 10 or Body Surface Area (BSA) \>10 or Dermatology Life Quality Index (DLQI) \>10) * Indication for treatment with an IL17 or an IL23 inhibitor based on disease characteristics and comorbidities Exclusion Criteria: * Prior treatment with an IL17 or an IL23 inhibitor * Prior therapy with an TNFa-inhibitor for up to 3 months before entering the study * Chronic or severe acute infections, malignancy * Pregnancy or lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis cardiovascular disorder psoriasis psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerosis Cardiovascular disease Psoriasis

Contacts and locations

Locations

  • Andreas Sygros Hospital

    Athens, 17124, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.